Open, pending, and completed studies
MiraKind has a pipeline of open and pending studies to help determine the best ways to protect the health of individuals with the KRAS-variant, ranging from best first cancer management strategies to hormone replacement therapy to pregnancy-associated breast cancer.
Multiple Primary Cancers
This study will investigate how breast cancer treatments that KRAS-variant women undergo during their first breast cancer diagnosis impact their risk for a second, independent breast cancer. This study will help 1 in 5 women with breast cancer know which treatments mitigate their risk of second breast cancers. Study participants do not need to know their KRAS-variant status in order to participate.
and Family Registry
This is an ongoing registry for individuals who have tested positive for the KRAS-variant and their genetically-related family members. Participants will be asked to complete a health survey every 6 to 12 months that will be used to observe changes in health over time, and will be applied to MiraKind's prevention research.
The KRAS-variant and Pregnancy Associated Breast Cancer
This is a study to determine if women with the KRAS-variant are more likely to develop pregnancy associated breast cancer, which is breast cancer diagnosed within five years of being pregnant.
The KRAS-variant, endometriosis and ovarian cancer
This is a study to better understand the association between the KRAS-variant, endometriosis and ovarian cancer. The KRAS-variant is the first genetic marker associated with endometriosis, has been shown to be a significant risk factor for ovarian cancer, and endometriosis is a risk for ovarian cancer. If you have endometriosis, please join and help us understand how different management strategies can help prevent ovarian cancer.
Hormones, the KRAS-variant and Breast Cancer Risk
This study examined the relationship between hormone replacement therapy and other types of hormone exposures and breast cancer risk for women with and without the KRAS-variant. This study is closed for enrollment and analysis is finalized. The paper is ready for submission for publication in a leading medical journal. The study results will be presented at San Antonio Breast Conference.